3M 2006 Annual Report Download - page 47
Download and view the complete annual report
Please find page 47 of the 2006 3M annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.
Health Care Business without Pharmaceuticals:
2006 2005 2004
Sales (millions) $3,237 $2,963 $2,803
Sales change analysis:
Local currency (volume and price) 8.5% 5.3% 2.9%
Translation 0.7 0.4 4.2
Total sales change 9.2% 5.7% 7.1%
Operating income (millions) $ 806 $ 888 $ 779
Percent change (9.1)% 14.0% 12.8%
Percent of sales 24.9% 30.0% 27.8%
7KHIROORZLQJGLVFXVVLRQSURYLGHVLQIRUPDWLRQRQ0+HDOWK&DUH¶VUHPDLQLQJEXVLQHVVHVDIWHUWKHVDOHRI
pharmaceuticals).
,QWRWDOWKHFRPELQDWLRQRIWKHIROORZLQJLWHPVQHJDWively impacted 2006 fourth quarter and total year operating
LQFRPHE\PLOOLRQ+HDOWK&DUHZLWKRXWSKDUPDFHXWicals included $95 million of expensed in-process research
and development costs related to the Brontes acquisition. Business-specific restructuring actions totaled $15 million,
primarily comprised of severance and reODWHGEHQHILWVSOXVDVVHWLPSDLUPHQWV
,QVDOHVZHUHELOOLRQ2UJDQLFORFDOFXUUHQF\growth was 7.4%, with acquisitions adding an additional
RIJURZWK/RFDOFXUUHQF\JURZWKZDVOHGE\WKHPHGLFDOVXSSOLHVDQGGHQWDOEXVLQHVVHV*HRJUDSKLFDOO\ORFDO
IRUGHFUHDVHGLPSDFWHGE\UHVWUXFWXULQJLPpacts and other items as discussed in the preceding
paragraph, which negatively impacted operatLQJLQFRPHJURZWKE\
,QORFDOFXUUHQF\VDOHVJURZWKZDVOHGE\0¶V medical, dental and health infoUPDWLRQV\VWHPVEXVLQHVVHV
Operational efficiency helped drive a 14.0% increase in operating income in 2005.
Pharmaceuticals Business:
2006 2005 2004
Sales (millions) $ 774 $797 $793
Sales change analysis:
Local currency (volume and price) (3.5)% 0.3% (6.7)%
Translation 0.6 0.3 4.3
Total sales change (2.9)% 0.6% (2.4)%
Operating income (millions) $1,039 $226 $194
Percent change N/A 16.6% (10.5)%
Percent of sales N/A 28.4% 24.5%
,QWRWDOWKHFRPELQDWLRQRIWKHIROORZLQJLWHPVSRVLWLYely impacted total year 2006 pharmaceuticals operating income
E\PLOOLRQSULPDULO\LQWKHIRXUWKTXDUWHURI$VGLVFXVVHGLQ1RWHLQHDUO\'HFHPEHU2006, the Company
VROGLWVEUDQGHGSKDUPDFHXWLFDOVEXVLQHVVLQWKH$VLD3DFLILFUHJLRQLQFOXGLQJ$XVWUDOLDDQG6RXWK$IULFD7KH&RPSDQ\
DOVRVROGLWVEUDQGHGSKDUPDFHXWLFDOVEXVLQHVVLQWKH8QLWHG6WDWHV&DQDGDDQG/DWLQ$PHULFDLQODWH'HFHPEHU
The operating income gain related to these transactions, whicKLVLQFOXGHGLQSKDUPDFHXWLFDOVWRWDOHGELOOLRQ$V
GLVFXVVHGLQ1RWHPLOOLRQRIVHYHUDQFHDQGEHQHILWFRVWs were recorded in the fourth quarter of 2006 related to
worldwide staff overhead reduction actions taken to streamline the Company's cost structure in response to the sale
RI0¶VEUDQGHGSKDUPDFHXWLFDOVEXVLQHVV$VDOVRGLVFXVVHGLQ1RWHWKHSKDUPDFHXWLFDOVEXVLQHVVIRUWRWDO\HDU
2006 included $97 million in employee-related severance DQGEHQHILWVDQGPLOOLRQRIDVVHWLPSDLUPHQWVDQGRWKHU
expenses. In addition, an environmental reserve of $13 million was recognized related to the pharmaceuticals
EXVLQHVV
In 2006, pharmaceuticals sales totaled $774 million, a local-FXUUHQF\VDOHVGHFUHDVHRI7KHHDUO\'HFHPEHU
VDOHRIWKHEUDQGHGSKDUPDFHXWLFDOVEXVLQHVVLQWKH$VLD3DFLILFUHJLRQQHJDWLYHO\LPSDFWHGWRWDO\HDU
FXUUHQF\VDOHVJURZWKZDVVWURQJHVWLQWKH8QLWHG6WDWHV(XURSHDQG$VLD3DFLILFDUHDV2SHUDWLQJLQFRPH